An interventional study of LungTrainers and LungTrainers Pulmonary Rehabilitation regime in Non-cystic Fibrosis Bronchiectasis, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-06.
Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Bronchiectasis with a site in United States — 21 open to participants now, 23 under way, 2 of them phase 3. Bronchiectasis · United States.
Among the 65 studies in Bronchiectasis with a site in United States, this one is the 31st largest by planned enrollment of the 52 interventional ones that give a count, is one of 8 that started in 2024, is one of 16 with no phase, reaches primary completion later than 6 of the 21 other live ones, and was the 45th registered.
405 studies on the registry are indexed under Bronchiectasis; 126 are open to participants now.
Browse Bronchiectasis studies →21 of the 65 studies in Bronchiectasis with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
UCB Biopharma SRL · Sites in United States
Ages 18–80
Indiana University · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 22 more countries
Ages 12+
GlaxoSmithKline · Sites in United States, Argentina, China and 9 more countries
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 94 Bronchiectasis studies recruiting now, 51 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 13 take children under 18; 27 take healthy volunteers.
This study: 21 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
First in 1988; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 60 across 263 interventional studies indexed under Bronchiectasis.
Median enrollment 78 across the 52 interventional studies, 100 across the 13 observational. Of the 39 that completed or were terminated, 20 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 65 have an industry lead sponsor. The 10 most frequent:
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
Mayo Clinic has 4 studies filed under Bronchiectasis — fewer than ten, so there is no comparison to draw.
8 of the studies in Bronchiectasis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06872892Phase 3Boehringer IngelheimThe AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis | 2027-06-15 |
| NCT05860803Mayo ClinicBreathing Training and Exercise Capacity in Non-CFB | 2026-12-01 |
| NCT07135284Synchrony-Medical, LtdReal Life Evaluation of the LibAirty Airway Clearance System in Adults With Bronchiectasis (RELACS) | 2027-02 |
| NCT05846230Boehringer IngelheimClairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine | 2027-03-31 |
| NCT03839992Gelb, Arthur F., M.D.Detection of Unsuspected Small Airways Obstruction in Cystic Fibrosis | 2027-04-25 |
Add all 8 to your calendar (.ics) → With an account.
Among the 65 studies in Bronchiectasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research is to investigate whether a home-based and health coach supported specific breathing and respiratory muscle training program improves the ability to exercise, the function of the lungs and breathing muscles, and general clinical status in people with non-cystic fibrosis bronchiectasis (non-CFB).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive pulmonary rehabilitation via standard physician directed care (i.e., 'normal care').
In addition standard of care pulmonary rehabilitation, subjects will participate in an 8-week home-based specific breathing and respiratory muscle training via the LungTrainers Pulmonary Rehabilitation regime (LT-PR).
Device: LungTrainers · Behavioral: LungTrainers Pulmonary Rehabilitation regime
A training device that provides a variable resistance against which users breathe out. Users breathe through a plastic mouthpiece that is connected to an acrylic cylinder via rubber tubing. The mouthpiece has several small holes of various diameters and up to three stainless steel weights (half-weight increments) can be inserted into the acrylic tube. With each breath-out, the user exhales against the resistance provided by the weight inserts, and each inspiration (i.e., breath-in) is unresisted. During each resisted exhalation, the weight inserts are 'lifted' within the acrylic tube depending on the level of expiratory pressure generated by the participant.
Series of different exercises using the LungTrainers device 3-5 days per week for approximately 10 weeks. Exercises complete in one long session (20-30 minutes) or be broken down into multiple shorter sessions (e.g., 3 x 10 minutes). A health coach will be assigned to guide participants through the LT-PR program.
Also known as: LT-PR
Change in six-minute walk test distance
Measures the distance walked in meters for 6 minutes.
Time frame: Baseline, 8 weeks
Change in peak oxygen uptake during maximal incremental exercise test
Maximum volume or amount of oxygen consumption during cardiopulmonary exercise test (treadmill or cycle).
Time frame: Baseline, 8 weeks
Change in exercise time during maximal incremental exercise test
Maximum volume or amount of oxygen consumption during cardiopulmonary exercise test (treadmill or cycle).
Time frame: Baseline, 8 weeks
Peak exercise work rate during maximal incremental exercise test
Highest work rate achieved during cardiopulmonary exercise test (treadmill or cycle)
Time frame: Baseline, 8 weeks
Change in forced vital capacity
Measured by spirometry to determine the maximal amount of air that can be forcibly exhaled from the lungs after a full inhale, reported as liters (L).
Time frame: Baseline, 8 weeks
Change in forced expiratory volume in 1 second
Measured by spirometry to determine the volume of air that can be exhaled in 1 second with a forced breath.
Time frame: Baseline, 8 weeks
Change in maximal voluntary ventilation
Measured by spirometry to determine the largest amount of air inhaled and exhaled during maximal voluntary effort.
Time frame: Baseline, 8 weeks
Change in maximal inspiratory pressure
Assessed using a calibrated pressure meter to evaluate inspiratory muscle strength. After exhaling slowly and maximally (i.e., to residual volume), the subject will be urged strongly to 'suck-in as maximally as possible' (Mueller maneuver) for approximately 3 to 5 seconds. Measured by 3-5 repetitions and defined as the highest value (in cmH2O) of three measurements that vary by ≤5%.
Time frame: Baseline, 8 weeks
Change in maximal expiratory mouth pressure
Assessed using a calibrated pressure meter to evaluate expiratory muscle strength. After inhaling slowly and maximally (i.e., to total lung capacity), the patient will be strongly urged to 'blow-out as maximally as possible' (Valsalva maneuver) for approximately 3 to 5 seconds. Measured by 3-5 repetitions and defined as the highest value (in cmH2O) of three measurements that vary by ≤5%.
Time frame: Baseline, 8 weeks
Change in diaphragm thickness
Ultrasound-derived diaphragm thickness, reported centimeters (cm)
Time frame: Baseline, 8 weeks
Change in diaphragm thickening fraction
Ultrasound-derived diaphragm thickening fraction defined as ratio of at total lung capacity thickness at functional residual capacity to thickness at functional residual capacity, reported in millimeters (mm).
Time frame: Baseline, 8 weeks
Change in diaphragm excursion
Ultrasound-derived diaphragm excursion defined as the amplitude of excursion from baseline to the point of maximum height during the sniff, reported in centimeters (cm).
Time frame: Baseline, 8 weeks
Change in Modified Medical Research Council Dyspnea Scale (mMRC)
mMRC scale is a self-rating tool to measure the degree of disability that breathlessness poses on day-to-day activities on a scale from 0 to 4 which 0=no breathlessness except on strenuous exercise; 1=shortness of breath when hurrying on the level or walking up a slight hill; 2=walks slower than people of same age on the level because of breathlessness or has to stop to catch breath when walking at their own pace on the level; 3=stops for breath after walking approximately 100 m or after few minutes on the level; and 4=too breathless to leave the house, or breathless when dressing or undressing.
Time frame: Baseline, 8 weeks
Change in St. George's Respiratory Questionnaire (SGRQ)
SGRQ measures impact on overall health, daily life, and perceived well-being in patients with lung disease, specifically obstructive airways disease. The questionnaire consists of two parts with three components; Part 1: symptoms component (frequency \& severity) with a 1, 3 or 12-month recall (best performance with 3- and 12-month recall); Part 2: activities that cause or are limited by breathlessness; Impact components (social functioning, psychological disturbances resulting from airways disease) refer to current state as the recall. Scores range from 0 to 100, with higher scores indicating more limitations.
Time frame: Baseline, 8 weeks
Change in Dartmouth COOP Functional Assessment Charts
The Dartmouth COOP chart consists of nine questions measuring seven domains of health status: physical fitness, feelings, daily activities, social activities, change in health status, current overall health perceptions, bodily pain, social support, and quality of life. Each question has five response options.
Time frame: Baseline, 8 weeks
Plan to share: No
Started Jan 2024 (actual). Primary completion is estimated for Dec 2026, 34 months after the start.
Of 73 non-industry interventional studies with no phase under Bronchiectasis, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 67. This study's planned 34 months is above that.
Counting every sponsor, half of 79 studies reached it within 20 months; a quarter within 10 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.